-transparent.png){kind=logo}
Cisplatin today is a cornerstone of combination chemotherapy for ovarian cancer. Carboplatin seems equal to cisplatin in antitumour activity, but has a different toxicity profile. After a feasibility study, a randomized phase III study in ovarian cancer stage II, III, and IV was undertaken, comparing carboplatin with cisplatin in combination with cyclophosphamide, doxorubicin and hexamethylmelamine. Preliminary analysis of this study reveals no statistically significant difference in response rate. Notwithstanding equal haematological toxicity, the other side effects evoked by carboplatin in combination treatment are much milder than those evoked by cisplatin. Further analysis will be necessary to draw definite conclusions about the results obtained.
W W ten Bokkel Huinink, and
M E van der Burg, and
A T van Oosterom, and
J P Neijt, and
M George, and
J P Guastalla, and
C H Veenhof, and
N Rotmensz, and
O Dalesio, and
J B Vermorken
January 2005,
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
W W ten Bokkel Huinink, and
M E van der Burg, and
A T van Oosterom, and
J P Neijt, and
M George, and
J P Guastalla, and
C H Veenhof, and
N Rotmensz, and
O Dalesio, and
J B Vermorken
February 1992,
Seminars in oncology,
W W ten Bokkel Huinink, and
M E van der Burg, and
A T van Oosterom, and
J P Neijt, and
M George, and
J P Guastalla, and
C H Veenhof, and
N Rotmensz, and
O Dalesio, and
J B Vermorken
February 1992,
Seminars in oncology,
W W ten Bokkel Huinink, and
M E van der Burg, and
A T van Oosterom, and
J P Neijt, and
M George, and
J P Guastalla, and
C H Veenhof, and
N Rotmensz, and
O Dalesio, and
J B Vermorken
January 2004,
The oncologist,
W W ten Bokkel Huinink, and
M E van der Burg, and
A T van Oosterom, and
J P Neijt, and
M George, and
J P Guastalla, and
C H Veenhof, and
N Rotmensz, and
O Dalesio, and
J B Vermorken
January 1991,
European journal of cancer (Oxford, England : 1990),
W W ten Bokkel Huinink, and
M E van der Burg, and
A T van Oosterom, and
J P Neijt, and
M George, and
J P Guastalla, and
C H Veenhof, and
N Rotmensz, and
O Dalesio, and
J B Vermorken
October 2004,
Nihon rinsho. Japanese journal of clinical medicine,
W W ten Bokkel Huinink, and
M E van der Burg, and
A T van Oosterom, and
J P Neijt, and
M George, and
J P Guastalla, and
C H Veenhof, and
N Rotmensz, and
O Dalesio, and
J B Vermorken
January 1994,
European journal of gynaecological oncology,
W W ten Bokkel Huinink, and
M E van der Burg, and
A T van Oosterom, and
J P Neijt, and
M George, and
J P Guastalla, and
C H Veenhof, and
N Rotmensz, and
O Dalesio, and
J B Vermorken
May 1996,
Chinese medical journal,
W W ten Bokkel Huinink, and
M E van der Burg, and
A T van Oosterom, and
J P Neijt, and
M George, and
J P Guastalla, and
C H Veenhof, and
N Rotmensz, and
O Dalesio, and
J B Vermorken
July 2001,
Oncology (Williston Park, N.Y.),
W W ten Bokkel Huinink, and
M E van der Burg, and
A T van Oosterom, and
J P Neijt, and
M George, and
J P Guastalla, and
C H Veenhof, and
N Rotmensz, and
O Dalesio, and
J B Vermorken
November 2011,
Acta obstetricia et gynecologica Scandinavica,
